Compare NetApp Inc. (NTAP) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
NetApp Inc. vs Sana Biotechnology Inc — how do they compare? NetApp Inc. trades at $237.15 (market cap $45.38B), while Sana Biotechnology Inc trades at $2.79 (market cap $836.71M). The key difference: NetApp Inc. is far larger — about 54.2× Sana Biotechnology Inc's market cap, and NetApp Inc. pays a 0.9% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold NetApp Inc. for 56 Days and Sana Biotechnology Inc for 23 Days on average.
| NTAP | SANA | |
|---|---|---|
Market Cap | $45.38B | $836.71M |
Volume | 2,264,311 | 4,507,444 |
Sector | Technology | Health |
52-Week High | $237.15 | $5.92 |
52-Week Low | $94.11 | $2.68 |
Typical Hold Time | 56 Days | 23 Days |
Enterprise Value | $44.34B | $749.96M |
Dividend Yield | 0.9% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NTAP trades at $231.05, down 2.03% today, with a bullish technical signal from moving averages and strong recent earnings beats. The company reported Q2 2026 EPS of $2.58, beating estimates of $2.12, and maintains robust profitability with a net margin of 19.19%. Recent news highlights strategic AI partnerships with Oracle and Supermicro, enhancing its data infrastructure offerings.
Outlook remains positive driven by AI demand and earnings momentum, though valuation multiples like a P/E of 32.63 suggest premium pricing. Risks include competitive pressures and execution of new initiatives. Analyst consensus is mixed with a $219.30 price target, below the current price, indicating potential near-term consolidation.
SANA Biotechnology trades at $2.79, up 2.57% today, but faces significant fundamental challenges with no revenue, negative earnings, and substantial cash burn. The technical picture remains bearish with moving averages signaling continued downward pressure, though oscillators show neutral conditions. Recent earnings have been mixed with two misses and one beat against expectations, while analyst sentiment remains overwhelmingly positive with 82% buy ratings.
The outlook hinges on SANA's clinical pipeline success and future revenue generation capabilities. Investment opportunity exists in the company's promising biotechnology platform and strong analyst support, but risks include continued cash burn, lack of current revenue, and execution challenges in bringing therapies to market. The stock represents a high-risk, high-reward biotechnology investment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About NetApp Inc.
NetApp is a leading provider of enterprise data management and storage solutions. The company's three operating business units are products, software maintenance, and hardware maintenance. NetApp transitioned from a data center storage firm to a company with software data management solutions for multicloud environments. The California-headquartered company sells globally and has approximately 10,000 employees.
Read more on NTAP →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
